Haleon plc

HLN.L · Healthcare · Drug Manufacturers - Specialty & Generic · Valued as of 2026-11-03 · Statements 2025-12-31

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

What it is worth

EPV + Growth

34.32B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

32.02B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

30.50B USD

15 years of cash for shareholders and lenders, less what is owed

Average Intrinsic Value

32.28B USD

The plain average of EPV, Profit and FCFF

Against the price

Market Cap

39.00B USD

the price on the date above times the shares

Intrinsic Value ÷ Market Cap

0.83×

the ratio the screener ranks by

Margin of Safety

-20.8%

1 − Market Cap / Average Intrinsic Value

Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.

Earnings power value plus growth: 34.32B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)38.80B USD
−②Net Debt Today9.87B USD
+③Growth Value5.39B USD
=Value34.32B USD

EPV of the Operations (NOPAT over WACC)

38.80B USD

Net debt today

-9.87B USD

Growth Value

+5.39B USD

Value

34.32B USD

①EPV (earnings power value)

38.80B USD

②Net Debt Today

9.87B USD

③Growth Value

5.39B USD

Market value

Market Cap39.00B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-13.6%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 32.02B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE17.31B USD
+②Equity at Year 15, Today14.71B USD
=Value32.02B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

17.31B USD

②Equity at Year 15, Today

14.71B USD

Market value

Market Cap39.00B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-21.8%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 30.50B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF21.97B USD
+②Invested Capital at Year 15, Today18.40B USD
−③Net Debt Today9.87B USD
=Value30.50B USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

21.97B USD

②Invested Capital at Year 15, Today

18.40B USD

③Net Debt Today

9.87B USD

Market value

Market Cap39.00B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-27.8%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 5.33%
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.24×Market Risk Premium 6.00%= 5.97%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 636.29M USDPretax Income 2.90B USD= 21.93%

The tax the interest saves.

Interest Expense =EBIT 3,368.82M USD−Pretax Income 2,901.04M USD= 467.78M USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 467.78M USDTotal Debt 11.57B USD×(1 − Tax Rate for WACC 21.93%)= 3.16%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 11.57B USDMarket Cap + Total Debt 39.00B USD + 11.57B USD= 22.88%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 77.12%×Cost of Equity 5.97%+Debt Weight 22.88%×Cost of Debt 3.16%= 5.33%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2025-12-31.

Total Assets 43.99B USD − Total Liabilities 21.77B USD = Book Value Today 22.22B USD

Total Debt 11.57B USD − Cash and Short-Term Investments 1.70B USD = Net Debt Today 9.87B USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 1-3.6%at most 5%passes8,905,305,590 / 9,234,573,831
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets3.0%at least -10.0%passes(3.55B USD − 2.25B USD) ÷ 43.99B USD
Price to bookMarket Cap ÷ Book Value Today1.75×at most 3×passes39.00B USD ÷ 22.22B USD
Operating marginOperating Income ÷ Revenue21.9%above 10.0%passes3.25B USD ÷ 14.87B USD
Revenue growthRevenue ÷ Revenue a Year Before − 15.4%above 10.0%does not pass14.87B USD / 14.11B USD
Net cash(Cash − Total Debt) ÷ Market Cap-25.3%above -30%passes(1.70B USD − 11.57B USD) ÷ 39.00B USD
Operating efficiencyOperating Income ÷ Gross Profit34.1%above 25.0%passes3.25B USD ÷ 9.54B USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Share price

331.53 GBp

Enterprise value

36.65B GBP

the provider's own figure

EV / EBITDA

12.86×

Price / book

1.80×

the provider's book

Price / earnings

18.40×

Return on equity

10.1%

the provider's figure, not this page's

Profit margin

14.5%

Revenue growth

2.2%

Analyst target, mean

418.89 GBp

Analysts

17

opinions in the consensus

Financial Statements

The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.

USD2022202320242025
Income statement

Revenue

13.10B14.41B14.11B14.87B

Gross profit

7.94B8.60B8.57B9.54B

Operating income

2.20B2.54B2.77B3.25B

EBITDA

operating income before depreciation and amortisation

2.63B3.00B3.30B3.85B

Pretax income

1.95B2.08B2.40B2.90B

Net income

1.28B1.34B1.81B2.25B

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

1.27B1.31B1.77B2.20B

R&D

362.05M396.42M374.34M425.99M
Balance sheet, year end

Total assets

42.02B43.41B43.11B43.99B

Total liabilities

22.16B22.08B22.73B21.77B

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

19.71B21.17B20.31B22.14B

Total debt

12.60B12.02B12.69B11.57B

Cash and equivalents

731.34M1.27B2.76B1.70B

Net PP&E

fixed assets after depreciation

2.29B2.42B2.41B2.69B

Working capital

current assets less current liabilities

-375.33M226.89M-118.08M-516.31M
Cash flow

Operating cash flow

2.49B2.68B2.89B3.55B

Capital expenditure

paid out, so below zero

-395.84M-428.29M-399.46M-556.75M

Depreciation and amortisation

346.36M393.87M407.00M485.30M

Free cash flow

operating cash flow plus capital expenditure

2.09B2.25B2.49B2.99B